{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:28:44Z","timestamp":1747153724961,"version":"3.40.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10072-020-04767-x","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T08:03:49Z","timestamp":1601539429000},"page":"3385-3389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5934-5535","authenticated-orcid":false,"given":"Claudia","family":"Altamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Cevoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Aurilia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Egeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Fofi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Torelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Pierangeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Favoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Fallacara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Pensato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Barbanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"4767_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/head.13459","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Greisman JD, Baigi K, Lipton RB (2019) Migraine progression: a systematic review. Headache J Head Face Pain 59:306\u2013338. https:\/\/doi.org\/10.1111\/head.13459","journal-title":"Headache J Head Face Pain"},{"key":"4767_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1468-2982.2007.01303.x","volume":"27","author":"L Kelman","year":"2007","unstructured":"Kelman L (2007) The triggers or precipitants of the acute migraine attack. Cephalalgia 27:394\u2013402. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01303.x","journal-title":"Cephalalgia"},{"key":"4767_CR3","doi-asserted-by":"crossref","unstructured":"Barbanti P, Aurilia C, Egeo G et al (2020) Erenumab in the prevention of high-frequency episodic and chronic migraine: EARLY (ErenumAb in Real Life in ItalY) study, the first Italian multicenter, prospective real-life study. Headache in press","DOI":"10.1111\/head.14032"},{"key":"4767_CR4","doi-asserted-by":"publisher","unstructured":"Vernieri F, Altamura C, Aurilia C et al (2020, 2020) Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study) [published online ahead of print, 2020 Aug 26]. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-020-04669-y","DOI":"10.1007\/s10072-020-04669-y"},{"key":"4767_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/head.13701","volume":"60","author":"CR Houts","year":"2020","unstructured":"Houts CR, Wirth RJ, McGinley JS et al (2020) Content validity of HIT-6 as a measure of headache impact in people with migraine: a narrative review. Headache 60:28\u201339. https:\/\/doi.org\/10.1111\/head.13701","journal-title":"Headache"},{"key":"4767_CR6","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Uwe R, Hallstrom Y et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377:2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"key":"4767_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/head.13691","volume":"60","author":"HC Detke","year":"2020","unstructured":"Detke HC, Millen BA, Zhang Q et al (2020) Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies. Headache 60:348\u2013359. https:\/\/doi.org\/10.1111\/head.13691","journal-title":"Headache"},{"issue":"6","key":"4767_CR8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1080\/00207454.2018.1554658","volume":"129","author":"V Lo Buono","year":"2019","unstructured":"Lo Buono V, Bonanno L, Corallo F et al (2019) Cognitive functions and psychological symptoms in migraine: a study on patients with and without aura. Int J Neurosci 129(6):588\u2013592. https:\/\/doi.org\/10.1080\/00207454.2018.1554658","journal-title":"Int J Neurosci"},{"issue":"1","key":"4767_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-016-0667-0","volume":"17","author":"G Santangelo","year":"2016","unstructured":"Santangelo G, Russo A, Trojano L et al (2016) Cognitive dysfunctions and psychological symptoms in migraine without aura: a cross-sectional study. J Headache Pain 17(1):76. https:\/\/doi.org\/10.1186\/s10194-016-0667-0","journal-title":"J Headache Pain"},{"key":"4767_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","volume":"158","author":"S Iyengar","year":"2017","unstructured":"Iyengar S, Ossipov MH, Johnson KW (2017) The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain 158:543\u2013559","journal-title":"Pain"},{"key":"4767_CR11","doi-asserted-by":"publisher","unstructured":"Avona A, Mason BN, Lackovic J et al (2020) Repetitive stress in mice causes migraine-like behaviors and CGRP-dependent hyperalgesic priming to a migraine trigger. Pain. https:\/\/doi.org\/10.1097\/j.pain.0000000000001953","DOI":"10.1097\/j.pain.0000000000001953"},{"key":"4767_CR12","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1111\/j.1526-4610.2009.01486.x","volume":"49","author":"KM Sauro","year":"2009","unstructured":"Sauro KM, Becker WJ (2009) The stress and migraine interaction. Headache J Head Face Pain 49:1378\u20131386. https:\/\/doi.org\/10.1111\/j.1526-4610.2009.01486.x","journal-title":"Headache J Head Face Pain"},{"key":"4767_CR13","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1212\/WNL.0000000000000332","volume":"82","author":"RB Lipton","year":"2014","unstructured":"Lipton RB, Buse DC, Hall CB et al (2014) Reduction in perceived stress as a migraine trigger. Neurology 82:1395\u20131401. https:\/\/doi.org\/10.1212\/WNL.0000000000000332","journal-title":"Neurology"},{"key":"4767_CR14","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1212\/WNL.0000000000000349","volume":"82","author":"PJ Goadsby","year":"2014","unstructured":"Goadsby PJ (2014) Stress and migraine: something expected, something unexpected. Neurology 82:1388\u20131389. https:\/\/doi.org\/10.1212\/WNL.0000000000000349","journal-title":"Neurology"},{"key":"4767_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10072-020-04543-x","volume":"2020","author":"IC Parodi","year":"2020","unstructured":"Parodi IC, Poeta MG, Assini A et al (2020) Impact of quarantine due to COVID infection on migraine: a survey in Genova, Italy. Neurol Sci 2020:1\u20133. https:\/\/doi.org\/10.1007\/s10072-020-04543-x","journal-title":"Neurol Sci"},{"key":"4767_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s10194-018-0907-6","volume":"19","author":"P Vo","year":"2018","unstructured":"Vo P, Fang J, Bilitou A et al (2018) Patients\u2019 perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain 19:82. https:\/\/doi.org\/10.1186\/s10194-018-0907-6","journal-title":"J Headache Pain"},{"issue":"5","key":"4767_CR17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/head.12561","volume":"55","author":"AK Black","year":"2015","unstructured":"Black AK, Fulwiler JC, Smitherman TA (2015) The role of fear of pain in headache. Headache. 55(5):669\u2013679. https:\/\/doi.org\/10.1111\/head.12561","journal-title":"Headache."},{"key":"4767_CR18","unstructured":"Istituto Superiore di Sanit\u00e0 EMICRANIA: UNA MALATTIA DI GENERE IMPATTO SOCIO-ECONOMICO IN ITALIA, 2018th ed"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04767-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-020-04767-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04767-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T01:38:42Z","timestamp":1633052322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-020-04767-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4767"],"URL":"https:\/\/doi.org\/10.1007\/s10072-020-04767-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"21 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Claudia Altamura received travel grants from Novartis, Lusofarmaco, Laborest. Sabina Cevoli received honoraria as speaker panels, for participating in advisory boards from Teva, Allergan, and Novartis. Cinzia Aurilia received travel grants from Eli-Lilly, FB-Health, Lusofarmaco, and Teva. Gabriella Egeo received travel grants and honoraria from Eli-Lilly, Novartis, New Penta, and Ecupharma. Luisa Fofi received travel grants and honoraria for the advisory board from Teva, Eli-Lilly, and Novartis Paola Torell received travel grants and honoraria from Allergan, Teva, Eli-Lilly and Novartis Giulia Pierangeli received honoraria as a speaker, for participating in advisory boards or for investigation studies from Teva, Allergan, Novartis, Electrocore Valentina Favoni received honoraria as a speaker or for participating in advisory boards from Ely-Lilly, Novartis and Teva. Piero Barbanti honoraria for advisory boards, speaker panels, or investigation studies from Alder, Allergan, Bayer, ElectroCore, Eli-Lilly, GSK, Lusofarmaco, MSD, Novartis, Stx-Med, Teva, Visufarma. Fabrizio Vernieri received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Allergan, Angelini, Eli-Lilly, Novartis, Teva. Nicoletta Brunelli, Adriana Falllacara, and Umberto Pensato have no conflict to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Campus Bio-Medico University Ethical Committee (prot 6\/19 OSS ComET CBM).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors provided consent for publication of the manuscript in the current form in Neurological Science.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}